glp-1 drugs chemically different clinically similar Designing delivery: structural perspectives and formulation approaches for optimized therapy What is GLP-1 & Does

Consistent with these findings, previous in vitro studies showed that OXM is a full agonist at the GCGR and GLP-1R but is 3-fold less potent at the GCGR than native glucagon and 100-fold less potent at the GLP-1R than native GLP-1, in terms of activating cAMP accumulation ( Despite convincing data suggesting the central role of GLP-1R signalling in the food intake reduction effects of OXM, there were still some unexplained effects of the gut hormone including increased energy expenditure, suggesting a GLP-1R independent mechanism of action ( in vitro in addition to enhanced metabolic rate in humans had been previously shown ( Glp1r -/- mice, suggesting that both GLP-1R and GCGR are required for weight loss to occur

Chia CW, Carlson OD, Kim W, Shin YK, Charles CP, Kim HS, et al

The dose-response analysis determined an ED of 242.9 mg/kg and a maximum efficacy (E max ) of 54%, based on 1-h post-administration values [71]

Prominent players in the GLP-1 market include Novo Nordisk, Eli Lilly and Company, Pfizer Inc., AstraZeneca Plc, and others

Alternatively, explore our Community to discover new perspectives on Hims & Hers Health

then, if you like the math model, you can decide whether it fits your budget for extended sessions